The difference between the two groups was statistically significant (P = 0.034), suggesting that patient prognosis analysis needs to be overlaid with a focus on all time points rather than specific time points and that anti-MDA5 antibody positivity is strongly associated with poor prognosis throughout the course of combined ILD in patients with PM/DM. Here, IFIH1 is linked to interstitial lung disease.